



20 May 2024

Company Announcements Office  
Australian Securities Exchange

### **Passing of Vectus' Chief Executive Officer (CEO)**

It is with great sadness and regret that Vectus Biosystems Limited (Vectus) announces the death of Dr Karen Duggan, the Company's Co-Founder and CEO. Before Dr Duggan tragically succumbed to a recent illness, she expressed her desire to see the technologies that she helped pioneer utilised for the benefit of humanity.

The Board and all of Vectus' team express our deepest and sincerest condolences to her family and friends. Karen was a visionary, a world-leading Nephrologist and a Research Scientist of outstanding talent. We wish to recognise her unparalleled contributions to cardiovascular science and medicine.

The Company anticipates making an announcement this week in relation to the appointment of an interim Chief Technology Officer well-versed in Vectus' science and technology. The Company will be undertaking a number of steps with the aim of bringing Vectus' singular portfolio to commercial fruition.

Dr Ron Shnier said: "The past few years have been an absolute privilege to be working with a Scientist and Physician of Karen's calibre and commitment."

### **Vectus Biosystems Limited**

**Dr Ron Shnier**  
Chairman

This announcement was authorised by the Company's Board of Directors.

### **About Vectus Biosystems Limited**

The Company is developing a treatment for fibrosis and high blood pressure, including for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising \$5.1 million. Funds from the IPO were predominantly used to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following the successful results from the 2019 fundraising via convertible notes, which were all subsequently converted into shares, and the 2020 and 2022 share placements, and share purchase plan, the Company has funding for its Human Phase Ib trial of VB0004, and to advance it and the other drugs in its library. Vectus' strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.

The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus' wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems. The Company's current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.

**VECTUS BIOSYSTEMS LIMITED** ABN 54 117 526 137

Level 3, 11 Julius Avenue, North Ryde, NSW 2113 Australia Telephone: +61 2 8876 8200 Facsimile: +61 2 9662 1720  
Email: [info@vectusbiosystems.com.au](mailto:info@vectusbiosystems.com.au)  
Website: [www.vectusbiosystems.com.au](http://www.vectusbiosystems.com.au)